Patients with PEComa harboring TSC2 mutations who are treated with mTOR inhibitors have a better objective response rate and progression-free survival than patients with TSC1 mutations. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.